Compare AbbVie Inc (ABBV) vs iShares MSCI China ETF (MCHI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs iShares MSCI China ETF — how do they compare? AbbVie Inc trades at $253.67 (market cap $449.91B), while iShares MSCI China ETF trades at $52.9. The key difference: AbbVie Inc pays a 2.72% dividend while iShares MSCI China ETF pays none, and AbbVie Inc is trading nearer its 52-week high, iShares MSCI China ETF nearer its low. Which is the better fit depends on your goals.
| ABBV | MCHI | |
|---|---|---|
Market Cap | $449.91B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $261.07 | $66.99 |
52-Week Low | $184.85 | $50.48 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
MCHI trades at $52.02, up 2.18% today, amid a bearish technical signal with moving averages indicating selling pressure and oscillators neutral. The stock faces resistance at $52. Recent news highlights China's AI and export-driven factory rebound, which could benefit broad China ETFs like MCHI, but structural headwinds and value trap risks persist according to some analysts.
The outlook remains cautious due to mixed technicals and macroeconomic uncertainties. Opportunities exist if China's tech and manufacturing recovery accelerates, but risks include U.S.-China tensions, deflationary pressures, and potential regulatory changes. Investors should weigh the ETF's exposure to China's cyclical sectors against its attractive valuation multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About iShares MSCI China ETF
MCHI is an ETF that seeks to track the investment results of the MSCI China Index. It provides broad exposure to the Chinese equity market, primarily focusing on large and mid-cap companies listed in Hong Kong and Shanghai. MCHI serves as a core holding for investors looking to gain diversified exposure to the performance and growth potential of the companies within the People's Republic of China.
Read more on MCHI →
